Ivo Abraham, PhD, MS, RN

Ivo Abraham Headshot
abraham@pharmacy.arizona.edu

Ivo Abraham is a professor in the Department of Pharmacy Practice and Science, R. Ken Coit College of Pharmacy, with joint appointments in the Department of Family and Community Medicine and the Department of Clinical Translational Sciences. He has also served on the faculty of Case Western Reserve University, University of Virginia, and (part-time) KU Leuven (Belgium); and as a visiting professor at universities in the US, Europe, and Asia.

Having been a member of several editorial boards, he currently serves as the Quantitative Methods Editor of JAMA Dermatology and as Editor-in-Chief of the Journal of Medical Economics. In the US, he has served as a chartered or ad hoc study section member for the NIH, NIMH, AHRQ, VA, and NSF since 1985. He has served as an expert adviser to the Innovative Medicines and Innovative Health Initiatives, a joint 7.4 billion euro undertaking of the European Union and the industry to stimulate research and innovation in human therapeutics, vaccines, as well as diagnostics and other technologies, from their inception in 2008. He has also served as an expert to various public and private funding agencies in European, Asian, and North American countries.

His educational and scientific honors and awards include several named lectureships in the US and abroad; and an invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008).

Cancer Focus

A nurse by profession and an outcomes, effectiveness, and economics researcher by trade, his research has been funded since 1984 by public funding agencies, foundations, and corporations. He coordinates the Senza Nome (Italian, “without a name”) research group, which, on the outcomes and effectiveness side, studies how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes; and how practicing in accordance with evidence-based guidelines translates into better patient outcomes. On the economics side, his group tries to reconcile four questions: what is the clinical effect? how much does it cost? is it worth it? and, can we afford it?

Research Program Role
Cancer Prevention and Control Program

Display Name
Ivo Abraham, PhD, MS, RN

Publications

Eckstrom J, Bartels T, Abraham I, Patel H, Elquza E, Scott AJ, Malangone S, Hollings J, McBride A. 2019. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI. Support Care Cancer. 27:873–878. doi:10.1007/s00520-018-4373-0.

Algotar A, Hsu C-H, Sherry Chow HH, Dougherty S, Babiker HM, Marrero D, Abraham I, Kumar R, Ligibel J, Courneya KS, et al. 2019. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Protocol for a Feasibility and Exploratory Efficacy Study in Men on Androgen Deprivation Therapy. JMIR Res Protoc. 8:e12579. doi:10.2196/12579.